drugset / Trial / NCT04958265
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.
Timeline
- Start
- 2021-11-17
- Primary completion
- 2025-07-04
- Completion
- 2029-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crovalimab | Monoclonal antibody | 680 mg | Intravenous |
| Subject | Crovalimab | Monoclonal antibody | 1020 mg | Intravenous |